China Pharma Holdings, INC 8-K filings

China Pharma Holdings Inc. announced the pricing of a registered direct offering, raising $5 million in gross proceeds to fund working capital and general corporate purposes.

China Pharma Holdings, Inc. subsidiary Helpson acquired an invention patent for Prinsepia Utilis Esterol Sublingual Tablets for $6.93 million, paid in common stock.

China Pharma Holdings' subsidiary, Helpson, has acquired an invention patent for a Topiroxostat Nanoemulsion for $8.82 million, paid in company stock.

China Pharma Holdings' stockholders approved a reverse stock split, elected three independent directors, and adopted an amendment to its long-term incentive plan at its annual meeting.

China Pharma Holdings, Inc. subsidiary Helpson acquired an invention patent for Ipragliflozin tablets for $9.8 million, paid in common stock.

China Pharma Holdings, Inc. subsidiary Helpson acquired an invention patent for a Captopril microcapsule and its preparation method for $6.3 million, paid in 3.5 million restricted common shares.

China Pharma Holdings Inc. will implement a 1-for-10 reverse stock split on April 15, 2025.

China Pharma Holdings has rescinded a securities purchase agreement with an investor, effectively voiding the deal from its inception.

China Pharma Holdings held its annual meeting on December 22, 2024, where shareholders approved a reverse stock split, elected directors, and adopted an incentive plan amendment.

China Pharma Holdings has entered into a securities purchase agreement for an at-the-market offering to potentially raise up to $600,000 by selling common stock to an institutional investor.

China Pharma Holdings has extended the maturity date of a convertible promissory note to August 19, 2025, and reduced its minimum monthly redemption amount.

China Pharma Holdings has terminated its engagement with B F Borgers CPA PC and appointed Enrome LLP as its new independent auditor following an SEC order against Borgers.

China Pharma Holdings has successfully regained compliance with NYSE American listing standards after a reverse stock split, resolving concerns about its low stock price.

China Pharma Holdings will implement a 1-for-5 reverse stock split of its common stock, effective March 6, 2024.

China Pharma Holdings' subsidiary, Hainan Helpson, has acquired a patent for a psoriasis treatment in exchange for $1.5 million in company stock and a 10% share of future profits.